AGIO
Agios Pharmaceuticals, Inc.
stock NASDAQ

The biotech winter is over. Finally.
You’re missing a few things in your thesis.
The faster FDA is critical, obviously, but we have AI appearing in various areas of biotech which is helping researchers and scientists. Immensely.
There is a massive patent cliff that is driving biotech M&A valuations through the roof.
There’s also an older population that is more in need of new treatments since people are living longer.
Nanotechnology and robotics and breakthroughs in peptides and targeted radiotherapy treatments, etc are going to continue to force biotechs to keep up with innovation.
I am long on numerous biotechs including: SLS, DRTS, AGIO, BMEA, CADL, COGT, CRBP, DTIL, IDYA, IMUX, IRON, JBIO, LFWD, NRIX, OLMA, QTTB, REPL, SYRE, TNGX, VERA, VERU, VRDN, ZLAB and ZYME.

The biotech winter is over. Finally.
You’re missing a few things in your thesis.
The faster FDA is critical, obviously, but we have AI appearing in various areas of biotech which is helping researchers and scientists. Immensely.
There is a massive patent cliff that is driving biotech M&A valuations through the roof.
There’s also an older population that is more in need of new treatments since people are living longer.
Nanotechnology and robotics and breakthroughs in peptides and targeted radiotherapy treatments, etc are going to continue to force biotechs to keep up with innovation.
I am long on numerous biotechs including: SLS, DRTS, AGIO, BMEA, CADL, COGT, CRBP, DTIL, IDYA, IMUX, IRON, JBIO, LFWD, NRIX, OLMA, QTTB, REPL, SYRE, TNGX, VERA, VERU, VRDN, ZLAB and ZYME.